Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors
Open accessThe DOI matches its Crossref record; 32 of the 33 references it cites were found in a registry or an index; none of the 20 sources its claims cite is checked for support yet.
Abstract
Background and purpose: Depression is common after stroke and is often treated with antidepressant medications (AD). ADs have also been hypothesised to improve stroke recovery, although recent randomised trials were neutral. We investigated the patterns of in-hospital AD initiation after ischaemic stroke and association with clinical and readmission outcomes. Methods: All Medicare fee-for-service beneficiaries aged 65 or older hospitalised for ischaemic stroke in participating Get With The Guidelines-Stroke hospitals between April and December 2014 were eligible for this analysis. Outcome measures included days alive and not in a healthcare institution (home time), all-cause mortality and readmission within 1-year postdischarge. Propensity score (PS)-adjusted logistic regression models were used to evaluate the associations between AD use and each outcome measure. We also compared outcomes in patients prescribed selective serotonin reuptake inhibitors (SSRIs) AD versus those prescribed non-SSRI ADs. Results: Of 21 805 AD naïve patients included in this analysis, 1835 (8.4%) were started on an AD at discharge. Patients started on an AD had higher rates of depression and prior ischaemic stroke, presented with higher admission National Institutes of Health Stroke Scale score and were less likely to be discharged home. Similarly, patients started on an SSRI had lower rates of discharge to home. Adjusting for stroke severity, patients started on an AD had worse all-cause mortality, all-cause readmission, major adverse cardiac events, readmission for depression and decreased home-time. However, AD use was also associated with an increased risk for the sepsis, a falsification endpoint, suggesting the presence of residual confounding. Conclusions: Patients with ischaemic stroke initiated on AD therapy are at increased risk of poor clinical outcomes and readmission even after PS adjustment, suggesting that poststroke depression requiring medication is a poor prognostic sign. Further research is needed to explore the reasons why depression is associated with worse outcome, and whether AD treatment modifies this risk or not.
Overview
CoChat Summary
TL;DR
In this national retrospective registry analysis of Medicare fee-for-service patients aged 65+ hospitalized for ischaemic stroke, 8.4% of 21,805 antidepressant-naïve patients were newly started on an antidepressant at discharge. Those started on antidepressants had worse 1-year outcomes after adjustment, including lower home time, higher mortality, and more readmissions, though the sepsis falsification endpoint suggested residual confounding.
Key findings
- Among 21,805 antidepressant-naïve patients from 999 hospitals, 1,835 (8.4%) were started on an antidepressant at discharge.
- After overlap-weight adjustment, antidepressant initiation was associated with shorter home time and worse 1-year outcomes, including all-cause mortality, all-cause readmission, MACE, and readmission for depression or non-cardiovascular reasons.
- No difference was observed in stroke/TIA or cardiovascular readmissions between the antidepressant and no-antidepressant groups after adjustment.
- The association with readmission for sepsis, used as a falsification endpoint, persisted after adjustment, suggesting residual confounding.
Methods
- Retrospective analysis of the Get With The Guidelines-Stroke Registry linked to Centers for Medicare & Medicaid Services data.
- Included Medicare fee-for-service beneficiaries aged 65 or older with a final clinical diagnosis of ischaemic stroke, discharged April–December 2014, excluding hospice/AMA discharge, in-hospital death, missing discharge antidepressant documentation, fee-for-service ineligibility, and contraindications to antidepressants.
- Used propensity score overlap weighting and regression models to compare antidepressant vs no antidepressant, and SSRI vs non-SSRI, on 1-year home time, mortality, readmission, and related endpoints.
Limitations
- The paper states this was a retrospective analysis of a national registry during a finite time period, which may limit generalisability.
- The paper states that indication, dose, duration, and adherence to antidepressant/SSRI treatment were not available, and direct information on poststroke depression rates was also lacking.
- Evident from the text: residual confounding likely remains, because the antidepressant group also had increased sepsis readmission, the falsification endpoint.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 0 Not valid · 5 Not checked · 39 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“were less likely to be discharged home”
- Also stated in: § Results · plain
“On discharge, the group started on an AD were less likely to be ambulatory or discharged home.”
§ Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors > Abstract > Results
plainstates an associationn = 1,835- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“no difference was observed in stroke/TIA or CV readmissions between the AD and no AD groups”
- Also stated in: § Discussion · plain
“no difference in stroke or TIA readmission”
§ Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Discussion · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“no difference was observed in rates of all-cause mortality or other readmissions”
§ Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“no difference was observed in rates of all-cause mortality or other readmissions”
§ Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“readmission for depression or non-CV reasons”
- Also stated in: § Results · plain
“non-CV readmission”
§ Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors > Results
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Results · plain
26 more claims
Create a free account to see all 44 claims and to verify the 20 references still open.
- The quote only partly states this claim. 2
- It may state two separate claims as one. 6
- Probably not a substantial claim. 6
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Chollet, F., Tardy, J., Albucher, J.-F., Thalamas, C., Berard, E., Lamy, C., Bejot, Y., Deltour, S., Jaillard, A., Niclot, P., et al. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70314-8 · Cited by 925
Towfighi, A., Ovbiagele, B., El Husseini, N., Hackett, M. L., Jorge, R. E., Kissela, B. M., Mitchell, P. H., Skolarus, L. E., Whooley, M. A., & Williams, L. S. (2017) · Stroke · doi:10.1161/str.0000000000000113 · Cited by 769
Schmidt, H. D., & Duman, R. S. (2007) · Behavioural Pharmacology · doi:10.1097/fbp.0b013e3282ee2aa8 · Cited by 648
Schwamm, L. H., Fonarow, G. C., Reeves, M. J., Pan, W., Frankel, M. R., Smith, E. E., Ellrodt, G., Cannon, C. P., Liang, L., Peterson, E., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.783688 · Cited by 568
Self-citationPost stroke depression: epidemiology, pathophysiology, and biological treatment
Whyte, E. M., & Mulsant, B. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01424-5 · Cited by 488
Kutlubaev, M. A., & Hackett, M. L. (2014) · International Journal of Stroke · doi:10.1111/ijs.12356 · Cited by 407
Fonarow, G. C., Reeves, M. J., Smith, E. E., Saver, J. L., Zhao, X., Olson, D. W., Hernandez, A. F., Peterson, E. D., & Schwamm, L. H. (2010) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.109.921858 · Cited by 345
Self-citationSchäbitz, W.-R., Schwab, S., Spranger, M., & Hacke, W. (1997) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199705000-00003 · Cited by 322
Depressive symptoms and history of depression predict rehabilitation efficiency in stroke patients
Gillen, R., Tennen, H., McKee, T. E., Gernert-Dott, P., & Affleck, G. (2001) · Archives of Physical Medicine and Rehabilitation · doi:10.1053/apmr.2001.26249 · Cited by 287 · cited 1×
“These findings suggest that the decision to start an ischaemic stroke patient on an AD identifies patients at risk for poor clinical outcomes, even after controlling for differences in stroke severity.”
Cited by
Kiper, P., Przysiężna, E., Cieślik, B., Broniec-Siekaniec, K., Kucińska, A., Szczygieł, J., Turek, K., Gajda, R., & Szczepańska-Gieracha, J. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s375754 · Cited by 80
“Furthermore, depression is associated with a worse functional outcome.(9) To date, PSD has typically been treated with pharmacological and psychotherapeutic therapies.”
BackgroundLekoubou, A., Nguyen, C., Kwon, M., Nyalundja, A. D., & Agrawal, A. (2023) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-023-01308-9 · Cited by 85
“N on - ph a r m ac o l og i ca l a pp r o ac h e s m a y b e p r e f e rr e d du e t o po t e n ti a l non - s t r ok e r e l a t e d c o m p li ca ti on s a nd n ee d t o b e f u r t h e r e xp l o r e d [ 52 , 53 ] .”
BackgroundLi, S. (2023) · Life · doi:10.3390/life13102061 · Cited by 73
“Depression is associated with less engagement in therapy and a worse functional outcome [42].”
BackgroundXiao, M., Chen, Y., & Mu, J. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114937 · Cited by 24
Yang, X., Ye, Q., Zhang, M., Xu, Y., & Yang, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1565420 · Cited by 2
Metadata
- Authors
- Etherton, M. R., Shah, S., Haolin, X., Xian, Y., Maisch, L., Hannah, D., Lindholm, B., Lytle, B., Thomas, L., Smith, E. E., Fonarow, G. C., Schwamm, L. H., Bhatt, D. L., Hernandez, A. F., & O'Brien, E. C.
- Affiliations
- Massachusetts General Hospital (US)
- Duke University (US)
- Duke Clinical Research Institute, Duke University, Durham, North Carolina, USA
- American Heart Association (US)
- University of Calgary (CA)
- University of California, Los Angeles (US)
- Brigham and Women's Hospital (US)
- Corresponding author
- Etherton, Mark R
- ORCID
- Venue
- Stroke and Vascular Neurology
- Publisher
- BMJ
- Published
- 2021-02-01
- Volume
- 6
- Issue
- 3
- Pages
- 384-394
- ISSN
- 2059-8688 (ISSN-L)
- 2059-8696
- PMC
- PMC8485250
- OpenAlex
- W3127367272
- Cited by
- 10
- References
- 33
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 1
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Stroke and Vascular Neurology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
- Funders
- American Heart Association (Get With The Guidelines -- Stroke)
- Patient-Centered Outcomes Research Institute (CE-1304-7073)
- Topics
- Health Sciences › Medicine › Rehabilitation › Stroke Rehabilitation and Recovery
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- antidepressant treatment, ischemic stroke, post-stroke depression, selective serotonin reuptake inhibitors, hospital readmission, all-cause mortality, stroke recovery, home discharge, residual confounding, sepsis, older adults
- MeSH terms
- Ischemic Stroke, Aftercare, Aged, Antidepressive Agents, Brain Ischemia, Medicare, Humans, Patient Discharge, United States, Survivors, Stroke
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. https://app.cochat.ai/papers/10.1136/svn-2020-000691
- The paper
- Etherton, M. R., Shah, S., Haolin, X., Xian, Y., Maisch, L., Hannah, D., Lindholm, B., Lytle, B., Thomas, L., Smith, E. E., Fonarow, G. C., Schwamm, L. H., Bhatt, D. L., Hernandez, A. F., & O'Brien, E. C. (2021). Patterns of antidepressant therapy and clinical outcomes among ischaemic stroke survivors. Stroke and Vascular Neurology. https://doi.org/10.1136/svn-2020-000691
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.